Intracranial hemorrhage is a serious, life-threatening condition associated with anticoagulation therapy. In-hospital mortality rate was 11.4% in the case series and 9.7% in the case reports.Ĭonclusions: Our analysis provides clinically relevant quantitative data regarding in-hospital mortality in idarucizumab/dabigatran-treated patients with ICH, which is estimated to be 9.7–11.4%.
Results: We identified six eligible studies (case series) with 386 patients and 54 single case reports. The assessed outcome was in-hospital mortality. Method: We searched PubMed and Scopus for all published cases of ICH in idarucizumab/dabigatran-treated patients until May 15, 2021. We aimed to estimate in-hospital mortality rate in these patients. Objectives: A review of all published dabigatran-related ICH cases treated with idarucizumab was performed. Systematic review of real-life mortality in these patients is missing. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran. 3Department of Vascular Disorders, University Clinical Centre Ljubljana, Ljubljana, Sloveniaīackground: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy.2Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.1Department of Vascular Neurology, Faculty of Medicine, University Clinical Centre Ljubljana, University of Ljubljana, Ljubljana, Slovenia.Senta Frol 1 * †, Dimitrios Sagris 2 †, Mišo Šabovič 3, George Ntaios 2 and Janja Pretnar Oblak 1
0 kommentar(er)
